Ambrx Biopharma Price to Sales Ratio 2020-2021 | AMAM

Historical PS ratio values for Ambrx Biopharma (AMAM) over the last 10 years. The current P/S ratio for Ambrx Biopharma as of June 28, 2022 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Ambrx Biopharma P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2022-06-28 2.64 inf
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.098B $0.007B
Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $170.283B 10.36
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.670B 16.84
Biohaven Pharmaceutical Holding (BHVN) United States $10.157B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.957B 0.00
Arcus Biosciences (RCUS) United States $1.815B 46.02
Emergent Biosolutions (EBS) United States $1.640B 7.02
Myovant Sciences (MYOV) United Kingdom $1.243B 0.00
Zymeworks (ZYME) Canada $0.354B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.098B 0.00
SQZ Biotechnologies (SQZ) United States $0.095B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00